DILIsym Awarded $1.5 Million Phase II NIH Grant
January 17 2019 - 8:30AM
Business Wire
Phase II Award of NIH Fast Track SBIR Grant
for Drug-induced Kidney Injury Software, RENAsym™, Funds
Development Over Next 20 Months
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP)
developing in silico modeling software, resources, and
information for assisting the pharmaceutical industry to more
efficiently develop safe and effective drug therapies, today
announced it has been awarded $1.5 million from Phase II of its
previously announced Fast-Track Small Business Innovation Research
(SBIR) grant by the National Institutes of Diabetes and Digestive
and Kidney Diseases (NIDDK). The second phase of the grant funding
will support DILIsym Services’ continued development, validation,
and testing of its RENAsym software for predicting drug-induced
kidney injury. Drug-induced kidney injury can be costly, and may
require multiple interventions, including hospitalization. The
development of the RENAsym software will provide a tool that can be
used in drug development efforts to predict a drug’s potential to
cause drug-induced kidney injury, as well as assess and improve the
understanding of mechanisms of drug-induced kidney injury.
Brett Howell, Ph.D., president of DILIsym Services, commented:
“Our success with Phase I of this Fast-Track NIH grant demonstrates
our commitment to help modernize drug development and reduce the
time and costs associated with developing new therapies. With this
continued NIH grant funding support, we will produce the first
commercial version of RENAsym. Our team is dedicated to the
development of commercial versions of RENAsym for use by the
pharmaceutical industry, academic centers, and government agencies
for investigation and screening of possible drug-induced kidney
damage.”
In parallel with, and at the conclusion of the grant funding,
the RENAsym Consortium is being formed to unite the world’s leading
biopharmaceutical companies within a pre-competitive arena to
collaborate, share ideas, and guide future development of RENAsym.
This new consortium is patterned after DILIsym Services’ highly
successful DILI-sim Initiative, which has developed tools to
predict and understand drug-induced liver injury. RENAsym will
utilize the PBPK module from GastroPlus®, the industry leading PBPK
modeling software, and eventually be offered as a module integrated
into the GastroPlus platform (as well as in a standalone
format).
Contact us to join the RENAsym Consortium
today!
About DILIsym Services, Inc.
DILIsym Services Inc. was founded in 2015 in Research Triangle
Park, North Carolina, and is the leading provider of drug-induced
liver injury simulation software and related consulting services to
the pharmaceutical industry. The company spun out of the former
Hamner Institutes, acquiring all of the intellectual property,
software, documentation, and other materials for the DILIsym®
software, a platform for predicting drug-induced liver injury. The
company’s other products include MITOsym®, for simulating in vitro
mitochondrial function, and NAFLDsym® for the study of nonalcoholic
fatty liver disease – a worldwide disease with few available
treatment options. More information is available on the company’s
website at https://www.dilisym.com.
About Simulations Plus, Inc.
Simulations Plus Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect,” and “anticipate”
mean that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190117005129/en/
Simulations Plus Investor
RelationsMs. Renee
Bouche661-723-7723renee@simulations-plus.com
Hayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024